Cytokinetics Gains Momentum with Positive Aficamten Results and New Regulatory Approval

Key Facts

Cytokinetics reported positive Phase 3 results for aficamten in the ACACIA-HCM trial, meeting primary endpoints for exercise performance and quality of life. Alongside this clinical success, the company received regulatory approval in Brazil for BEYONTTRA to treat ATTR-CM. To capitalize on this momentum, Cytokinetics announced the pricing of a public offering of common stock at $71.00 per share, aiming to raise $700 million. Additionally, underwriters have been granted an option to purchase up to 1,478,873 additional shares. This significant capital raise is expected to fund the commercialization of its cardiovascular pipeline and support global regulatory filings. These dual clinical and financial milestones reinforce the company's strategic position in the biotechnology sector.

Version History